190 related articles for article (PubMed ID: 22152933)
21. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
22. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
23. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Met pathway in lung cancer.
Belalcazar A; Azaña D; Perez CA; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2012 Apr; 12(4):519-28. PubMed ID: 22500688
[TBL] [Abstract][Full Text] [Related]
25. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
Maroun CR; Rowlands T
Pharmacol Ther; 2014 Jun; 142(3):316-38. PubMed ID: 24384534
[TBL] [Abstract][Full Text] [Related]
26. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
Feng Y; Thiagarajan PS; Ma PC
J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
[TBL] [Abstract][Full Text] [Related]
27. [MET: new target, new combinations].
Serrate C; Watson S; Vignot S
Bull Cancer; 2011 Jun; 98(6):689-96. PubMed ID: 21622087
[TBL] [Abstract][Full Text] [Related]
28. c-Met: structure, functions and potential for therapeutic inhibition.
Ma PC; Maulik G; Christensen J; Salgia R
Cancer Metastasis Rev; 2003 Dec; 22(4):309-25. PubMed ID: 12884908
[TBL] [Abstract][Full Text] [Related]
29. MET receptor tyrosine kinase as a therapeutic anticancer target.
Stellrecht CM; Gandhi V
Cancer Lett; 2009 Jul; 280(1):1-14. PubMed ID: 19100682
[TBL] [Abstract][Full Text] [Related]
30. Development of c-MET pathway inhibitors.
Liu X; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
[TBL] [Abstract][Full Text] [Related]
31. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.
Graziano F; Galluccio N; Lorenzini P; Ruzzo A; Canestrari E; D'Emidio S; Catalano V; Sisti V; Ligorio C; Andreoni F; Rulli E; Di Oto E; Fiorentini G; Zingaretti C; De Nictolis M; Cappuzzo F; Magnani M
J Clin Oncol; 2011 Dec; 29(36):4789-95. PubMed ID: 22042954
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer and the met hepatocyte growth factor receptor.
Knudsen BS; Edlund M
Adv Cancer Res; 2004; 91():31-67. PubMed ID: 15327888
[TBL] [Abstract][Full Text] [Related]
33. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
34. HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells.
Chen JT; Huang CY; Chiang YY; Chen WH; Chiou SH; Chen CY; Chow KC
Am J Respir Cell Mol Biol; 2008 May; 38(5):559-65. PubMed ID: 18096875
[TBL] [Abstract][Full Text] [Related]
35. Role of c-Met in cancer: emphasis on lung cancer.
Salgia R
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S52-8. PubMed ID: 19393836
[TBL] [Abstract][Full Text] [Related]
36. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
37. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
[TBL] [Abstract][Full Text] [Related]
38. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
[TBL] [Abstract][Full Text] [Related]
39. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
40. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
